Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Submitted by
admin
on July 17, 2017 - 9:15am
Source:
Endpoints
News Tags:
FDA
Amgen
osteoporosis
romosozumab
UCB Pharma
Radius Health
Tymlos
Headline:
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Do Not Allow Advertisers to Use My Personal information
